Advanced Pancreatic Cancer Outcome Boosted

Washington, D.C (eCanadaNow) - Using a therapy with a drug combination of three different medications is showing promise in treatment of advanced Pancreatic cancers.

The drugs bevacizumab, capecitabine, and gemcitabine when used together are proving to arrest the growth of tumors and stabilize patients that are suffering from advanced pancreatic cancer.

This new study that was led by scientists at Roswell Park Center Institute in Buffalo New York was released and the benefits of the three-drug combination appears to be marked.

The study involved 50 patients and revealed that the treatment is well tolerated for the most part and showed promise in tumor prevention and also kept tumors from progressing for as long as six months at a time.  

The overall median survival time for patients using this new treatment was also increased by 9.8 months on average.

This is a new study that is being presented at the American College of Clinical Oncology at their annual meeting in Chicago on Monday June 2, 2008.

Those patients that have advanced pancreatic cancer suffer from one of the most deadly cancers, and its survival rate is one of the lowest among common cancers. Nearly 38 thousand people will be diagnosed with pancreatic cancer in the United States in the year 2008, so the new study bears much promise for those patients diagnosed with pancreatic cancer.

Image Credit: Mayo Clinic